RESEARCH TRIANGLE PARK, NC, June 10, 2015 – G1 Therapeutics, Inc., a clinical-stage oncology company, announced today that Chief Business Officer Greg Mossinghoff will present a company overview at the BIO International Convention on Wednesday, June 17 at the Pennsylvania Convention Center in Philadelphia. The presentation will begin at 10:30 a.m. in Theater 4, "The Incredible Helix."

For additional information on the conference, please visit: http://convention.bio.org/.

About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. is a privately held clinical-stage pharmaceutical company based in Research Triangle Park, NC that focuses on the discovery and development of novel, small-molecule therapies to address significant unmet needs in oncology. The company is leveraging its proprietary kinase drug discovery platform to advance a pipeline of best-in-class compounds and first-in-class drug candidates that address two markets: CDK4/6 antineoplastics and protection of the bone marrow and immune system from damage by chemotherapy (chemoprotection).

###

Contact:                                                              
Mark Velleca, MD, PhD                
G1 Therapeutics                                              
919-213-9838                                                    
mvelleca@g1therapeutics.com                  

Media:
Laura Bagby                     
6 Degrees Communications
312-448-8098
lbagby@6degreespr.com